TransCode Therapeutics Awarded Funding from National Institutes of Health (NIH) to Support Clinical Evaluation of TTX-MC138
August 05 2021 - 7:30AM
Business Wire
-- TTX-MC138
targets MicroRNA10b for treatment of metastatic disease; TransCode
on track to submit exploratory investigational new drug (eIND)
application in Q1 2022 --
TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a platform company
solving the challenge of RNA delivery in oncology, today announced
that it has been awarded a Fast-Track Small Business Innovation
Research (SBIR) grant from the NIH to support the clinical
evaluation of TTX-MC138, TransCode’s lead therapeutic candidate for
the treatment of metastatic solid tumors. The award totals $2.3
million expected over three years.
“We are honored that the NIH recognizes and supports our mission
to overcome the obstacles of RNA delivery in oncology,” said
Michael Dudley, President and Chief Executive Officer of TransCode.
“We believe our TTX delivery platform offers tremendous potential
across a range of indications. Specifically, this SBIR grant will
help fund our planned first-in-human study of our lead candidate,
TTX-MC138, in patients with metastatic breast cancer. We look
forward to submitting an eIND application in the first quarter of
next year. This trial is designed to evaluate and demonstrate
proof-of-concept for the mechanism of action for our novel delivery
platform, potentially enabling TransCode to pursue a diverse
pipeline of TTX-based therapeutics.”
TransCode’s proprietary TTX platform leverages an iron oxide
nanoparticle as a novel, image-guided system to safely and
efficiently deliver oligonucleotides to their intended RNA target.
TTX-MC138 targets MicoRNA-10b, believed to drive metastatic
disease. The therapeutic has been validated preclinically in
multiple indications and has been shown to induce durable
regressions of metastatic disease in murine models of disseminated
breast cancer.
About TransCode Therapeutics
TransCode is an emerging RNA oncology company created on the
belief that cancer can be defeated through the intelligent design
and effective delivery of RNA therapeutics. The Company has created
a platform of drug candidates designed to target a variety of tumor
types with the objective of significantly improving patient
outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is
focused on treating metastatic cancer, which causes approximately
90% of all cancer deaths representing over nine million deaths per
year worldwide. The Company believes that TTX-MC138 has the
potential to produce regression without recurrence in a range of
cancers, including breast, pancreatic, ovarian and colon cancer,
glioblastomas and others. The Company’s other drug candidates,
TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by
targeting PD-L1 and Lin28b, respectively.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, without limitation, statements concerning the SBIR
grant, including the expected timing and receipt of the funds
thereunder, and statements concerning the planned first-in-human
study of TTX-MC138, including the timing of the planned eIND for
this study and the outcome of this study, including whether this
study will demonstrate proof-of-concept, and statements concerning
TransCode’s development programs and TTX technology platform
generally. Any forward-looking statements in this press release are
based on management’s current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: risk associated
with drug discovery and development; the risk that the results of
our planned clinical trials will not be consistent with our
pre-clinical studies or expectations; risks associated with the
timing and outcome of TransCode s planned regulatory submissions;
risks associated with TransCode’s planned clinical trials for its
product candidates; risks associated with obtaining, maintaining
and protecting intellectual property; risks associated with
TransCode’s ability to enforce its patents against infringers and
defend its patent portfolio against challenges from third parties;
the risk of competition from other companies developing products
for similar uses; risks associated with TransCode’s financial
condition and its need to obtain additional funding to support its
business activities, including TransCode’s ability to continue as a
going concern; risks associated with TransCode’s dependence on
third parties; and risks associated with the COVID-19 coronavirus.
For a discussion of other risks and uncertainties, and other
important factors, any of which could cause TransCode’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in TransCode’s
Final Prospectus for its initial public offering filed with the
Securities and Exchange Commission on July 9. 2021, as well as
discussions of potential risks, uncertainties and other important
factors in TransCode’s subsequent filings with the Securities and
Exchange Commission. All information in this press release is as of
the date of the release, and Allena undertakes no duty to update
this information unless required by law.
The names of other companies and products mentioned herein may
be trademarks of their respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210805005399/en/
Investor Contact: Josh Rappaport Stern Investor Relations
josh.rappaport@sternir.com
Company Contact: Tom Fitzgerald, CFO
tom.fitzgerald@transcodetherapeutics.com
TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
TransCode Therapeutics (NASDAQ:RNAZ)
Historical Stock Chart
From Apr 2023 to Apr 2024